Targeting TYRP1 With CAR T-cell Therapy May Help Treat Cutaneous and Rare Melanomas
A new chimeric antigen receptor (CAR) T-cell-based immunotherapy targeting TYRP1 may help treat patients with cutaneous and rare subtypes of melanoma, according to research out of the UCLA Health Jonsson Comprehensive Cancer Center. The new approach, as described in Nature Communications, uses an engineered CAR T-cell that is designed to recognize and attack cells with […]